Genomate - The right drug. The first time. Every time.

Therapy ranking for optimal decisions

Unlike traditional approaches, Genomate® goes beyond simplistic one-size-fits-all treatments by leveraging cutting-edge computational intelligence technology to analyze each patient's unique genetic alterations and biomarkers. This approach helps predict responses to multiple targeted therapies with unrivaled accuracy, ensuring patients receive the most effective treatment tailored to their needs.

With Genomate®, oncologists gain access to a comprehensive, data-backed report that serves as a roadmap for personalized cancer treatment. It empowers healthcare providers to make informed decisions that will optimize treatment outcomes for each patient.

of the cancer’s mutations are being considered

when choosing the right treatment (current solutions only target one mutation at a time)

improvement of mPFS (median progression-free survival)

when using Genomate-recommended treatments vs non-Genomate-recommended

SOURCE

of patients can receive
treatments of higher efficacy

when Genomate scores are considered

SOURCE

of pediatric cancer cases have been paired with matching targeted treatment when using Genomate

SOURCE

Our science

A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial

Cancer patients who received Genomate-recommended targeted therapy had a 4X higher positive response rate than those who received therapies selected based on the presence of a single biomarker but not recommended by Genomate AI in the SHIVA01 clinical trial.

SOURCE

Real-world performance of the digital drug-assignment system for precision oncology in lung cancer

2.6X longer overall survival and 3X longer progression-free survival of lung cancer patients.

SOURCE

Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors

Genomate identified actionable targeted treatment options for 72% of pediatric cancer patients, with the molecular tumor board approving these therapies in 78% of actionable cases (increased to 88% by 2020 due to continuous updates in the evidence database).

SOURCE

Genomate - the world’s first AI-powered clinical decision support that matches targeted therapies to the totality of available molecular information for each patient

30.2
million

new cancer cases
projected by 2040

16.3
million

cancer deaths
projected by 2040

2nd leading
cause

of deaths (to be
completed with copy)

Better treatment decisions lead to better patient outcomes.

The complexity of cancer, with its numerous types and genetic mutations, has long challenged the medical community. Each cancer is caused by a unique combination of over 6 million potential mutations of 600+ cancer genes.

The targeted therapies that currently exist are focused on only some of the most frequent cancer genes... and often fail to work due to the complex, unique molecular background of each tumor.

Genomate® is the right solution for:

Genomate Is the
Right Solution For:

Oncologists

Genomate equips oncologists with actionable insights derived from advanced computational intelligence-driven analysis, enabling them to make optimal treatment decisions for each patient, saving money on costly and ineffective therapies.

LEARN MORE

Biopharma companies

Genomate® dissects and analyzes the complex relationships between drugs, targets, genes, and diseases. This deep understanding of disease pathways enables the identification of novel therapeutic targets and can uncover potential targets that have previously been overlooked or misunderstood.

LEARN MORE

Partners

Genomate partners with healthcare organizations in their fight against cancer by unlocking the true promise of personalized medicine and matching the right treatments to the right patients. Genomate supports partners (payers, cancer centers, labs) in selecting cancer treatment options in their fight against cancer.

LEARN MORE